case 2: osimertinib in egfr-mutated lung cancer
Published 5 years ago • 236 plays • Length 3:09Download video MP4
Download video MP3
Similar videos
-
5:13
case 2: frontline therapy in egfr-mutated lung cancer
-
5:24
case 4: egfr mutation analysis post-osimertinib
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
5:00
case 2: testing for egfr in lung adenocarcinoma
-
30:32
2023 best of lung: targeted therapies in lung cancer
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies
-
3:06
exploring estrogen receptor roles and targeted therapy in nsclc
-
5:26
osimertinib’s value in egfr-mutant nsclc
-
5:55
a case of egfr-mutant non–small cell lung cancer
-
2:23
therapeutic strategies for egfr-mutated lung cancer
-
6:55
case 4: treating egfr nsclc after osimertinib
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
1:45
phase iii data support frontline osimertinib in egfr-mutant lung cancers
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
6:59
case 2: diagnosing pd-l1 and egfr lung adenocarcinoma
-
2:50
sequencing with osimertinib in egfr-mutated nsclc
-
1:41
egfr mutations in patients with lung cancer